Karyopharm Therapeutics
KPTI
89 hedge funds and large institutions have $610M invested in Karyopharm Therapeutics in 2015 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 41 increasing their positions, 18 reducing their positions, and 12 closing their positions.
128% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 18
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
5% more funds holding
Funds holding: 85 → 89 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $636M → $610M (-$25.8M)
31% less call options, than puts
Call options by funds: $2.86M | Put options by funds: $4.16M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$22.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$12.3M |
| 3 |
Millennium Management
New York
|
+$7.73M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.12M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.72M |
| 2 |
CGI
CI Global Investments
Oakland,
California
|
-$6.12M |
| 3 |
PC
PointState Capital
New York
|
-$4.59M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$4.07M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$3.92M |
KPTI Hedge Fund Activity: Q2 2015 in Review
89 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2015, worth a combined $610M — down 4.1% from $636M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new KPTI positions and 12 closed out — a net gain of 4 holders — while 41 added to existing stakes and 18 trimmed.
The largest buyer was Palo Alto Investors, adding an estimated $22.5M. The largest seller was PFM Health Sciences, cutting an estimated $8.72M.
- 89 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2015, up from 85 in Q1 2015.
- Funds reported $610M of Karyopharm Therapeutics stock for Q2 2015, down 4.1% quarter-over-quarter.
- 16 funds opened new Karyopharm Therapeutics positions in Q2 2015 and 12 closed out, a net change of +4 holders.
- The largest Karyopharm Therapeutics buyer in Q2 2015 was Palo Alto Investors, an estimated $22.5M added.
- The largest Karyopharm Therapeutics seller in Q2 2015 was PFM Health Sciences, an estimated $8.72M sold.
Based on aggregated 13F filings for Q2 2015.